Jose Manuel Otero, serving as the Chief Operating Officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), engaged in a divestment of company equity on July 1, 2026. The transaction involved the sale of 4,666 shares of the issuer's common stock, realizing a total monetary value of $20,903. The execution of this sale occurred through multiple trades, with the weighted average price recorded at $4.48 per share. The specific price points for these individual trades fluctuated between $4.35 and $4.73 per share.
The motivation behind this transaction was explicitly tied to the settlement of tax obligations. These liabilities arose from the release of performance Restricted Stock Units (RSUs) held by Mr. Otero. Prior to this divestment, on June 29, 2026, Mr. Otero had acquired 12,060 shares of common stock at a nominal price of $0.00 per share. Following the completion of these transactions, Mr. Otero's direct holdings in Lexeo Therapeutics common stock stood at 137,482 shares. This aggregate figure encompasses 100,621 RSUs, each conferring a contingent right to receive one share of common stock from the issuer.
Market valuation metrics indicate that the stock is currently trading at $4.45. This price point reflects a substantial decline of 55% over the preceding six-month period. The current valuation places the stock nearer to its 52-week low of $3.60 than to its 52-week high of $10.99. According to analysis provided by InvestingPro, the stock appears undervalued at these current levels. The platform suggests that investors seeking comprehensive financial metrics and additional ProTips may find further insights through their service.
In parallel with these insider transactions, Lexeo Therapeutics has made significant progress in its clinical development pipeline. The company published results from a Phase I/II study concerning its gene therapy candidate, LX2006, intended for the treatment of Friedreich ataxia. These findings were disseminated in JAMA Cardiology. The study cohort consisted of 17 participants who received varying doses of the therapy and were monitored over a duration spanning 6 to 36 months.
Furthermore, Lexeo has finalized both the protocol and the statistical analysis plan for its pivotal SUNRISE-FA 2 trial. This trial is designed to compare 13 treated participants against 13 untreated control participants. Notably, the study design excludes the use of a placebo or sham procedure. The objective of the SUNRISE-FA 2 trial is to further investigate the potential of LX2006 in addressing Friedreich ataxia cardiomyopathy. The company is currently awaiting final feedback from the FDA regarding this pivotal trial protocol and statistical analysis plan.
Raymond James has maintained a Strong Buy rating for Lexeo stock, keeping the price target at $25. These developments underscore the company's ongoing efforts to advance its gene therapy program. The intersection of insider activity and clinical milestones provides a snapshot of the current operational and market dynamics surrounding Lexeo Therapeutics.